Lattice stabilization and enhanced diffraction in human p38α crystals by protein engineering

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1696, Issue 1, 2004, Pages 67-73

  Patel, Sangita B ^a   Cameron, Patricia M ^a   Frantz Wattley, Betsy ^a   O'Neill, Edward ^a   Becker, Joseph W ^a   Scapin, Giovanna ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Lattice stabilization; Monodispersity; p38 ; Protein engineering; Reproducibility; Surface cysteine

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; DIFFRACTION; ENZYME STABILITY; GENE MUTATION; PRIORITY JOURNAL; PROTEIN ENGINEERING;

EID: 1242284175     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2003.09.009     Document Type: Article

References (30)

1. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., Berman K., Cobb M.H. Mitogen activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22:2001;153-183.
2. Adams J.L., Badger A.M., Kumar S., Lee J.C. King F.D., Oxford A.W. Progress in Medicinal Chemistry. vol. 38:2001;1-60 Elsevier, Amsterdam.
3. Drosos A.A. Newer immunosuppressive drugs - their potential role in rheumatoid arthritis therapy. Drugs. 62:2002;891-907.
4. Toledo L.M., Lydon N.B., Elbaum D. The structure-based design of ATP-site directed protein kinases inhibitors. Curr. Med. Chem. 6:1999;775-805.
5. Bridges A.I. Chemical inhibitors of protein kinases. Chem. Rev. 101:2001;2541-2572.
6. Scapin G. Structural biology in drug design: selective protein kinase inhibitors. DDT. 7:2002;601-611.
7. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science. 289:2000;1938-1942.
8. Davies T.G., Bentley J., Arris C.E., Boyle F.T., Curtin N.J., Endicott J.A., Gibson A.E., Golding B.T., Griffin R.J., Hardcastle I.R., Jewsbury P., Johnson L.N., Mesguiche V., Newell D.R., Noble M.E.M., Tucker J.A., Wang L., Whitfield H.J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol. 9:2002;745-749.
9. Fitzgerald C.E., Patel S.B., Becker J.W., Cameron P.M., Zaller D., Pikounis V.B., O'Keefe S.J., Scapin G. Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Struct. Biol. 10:2003;764-769.
10. Liverton N.J., Butcher J.W., Claiborne C.F., Claremon D.A., Libby B.E., Nguyen K.T., Pitzenberger S.M., Selnick H.G., Smith G.R., Tebben A., Vacca J.P., Varga S.L., Agarwal L., Dancheck K., Forsyth A.J., Fletcher D.S., Frantz B., Hanlon W.A., Harper C. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. 42:1999;2180-2190.
11. Natarajan S.R., Wisnoski D., Singh S.B., Stelmach J.E., O'neill E.A., Schwartz C.D., Thompson C.M., Fitzgerald C.E., O'keefe S.J., Kumar S., Hop C.E.C.A., Zaller D.M., Schmatz D.M., Doherty J.B. p38 MAP kinase inhibitors part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold. Bioorg. Med. Chem. Lett. 13:2003;273-276.
12. Stelmach J.E., Liu L., Patel S.B., Pivnichny J.V., Scapin G., Singh S., Hop C.E.C.A., Wang Z., Cameron P.M., Nichols E.A., O'Keefe S.J., O'Neill E.A., Schmatz D.M., Schwartz C.D., Thompson C.M., Zaller D.M., Doherty J.B. Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. 13:2003;277-280.
13. Wilson K.P., Fitzgibbon M.J., Caron P.R., Griffith J.P., Chen W., McCaffrey P.G., Chambers S.P., Su M.S.-S. Crystal structure of p38 mitogen-activated protein kinase. J. Biol. Chem. 271:1996;27696-27700.
14. Mateja A., Devedjiev Y., Krowarsch D., Longenecker K., Dauter Z., Otlewski J., Derewenda Z.S. The impact of Glu→Ala and Glu→Asp mutations on the crystallization properties of RhoGDI: the structure of RhoGDI at 1.3 A resolution. Acta Crystallogr., D Biol. Crystallogr. 58:2002;1983-1991.
15. Charron C., Kern D., Giege R. Crystal contacts engineering of aspartyl-tRNA synthetase from Thermus thermophilus: effects on crystallizability. Acta Crystallogr., D Biol. Crystallogr. 58:2002;1729-1733.
16. Nickerson D., Wong L.-L., Rao Z. An improved procedure for the preparation of X-ray diffraction-quality crystals of cytochrome P450cam. Acta Crystallogr., D Biol. Crystallogr. 54:1997;470-472.
17. Schwede T.F., Badeker M., Langer M., Retey J., Schulz G.E. Homogenization and crystallization of histidine ammonia-lyase by exchange of a surface cysteine residue. Protein Eng. 12:1999;151-153.
18. Hibi T., Hisada H., Nakatsu T., Kato H., Jun'ichi O.J. Escherichia coli B-glutamylcysteine synthetase: modification, purification, crystallization and preliminary crystallographic analysis. Acta Crystallogr., D Biol. Crystallogr. 58:2002;316-318.
19. Lisnock J.M., Tebben A., Frantz B., O'Neill E.A., Croft G., O'Keefe S.J., Li B., Hacker C., de Laszlo S., Smith A., Libby B., Liverton N., Hermes J.D., LoGrasso P. Molecular basis for p38 protein kinase inhibitor specificity. Biochemistry. 37:1998;16573-16581.
20. Boerner R.J., Kassel D.B., Barker S.C., Ellis B., DeLacy P., Knight W.B. Correlation of the phosphorylation states of pp60c-src with tyrosine kinase activity: the intramolecular pY530-SH2 complex retains significant activity if Y419 is phosphorylated. Biochemistry. 35:1996;9519-9525.
21. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1997;307-326.
22. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.-S., Kuszewski J., Nilges M., Pannu N.S., Read R.J., Rice L.M., Simonson T., Warren G.L. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr., D Biol. Crystallogr. 54:1998;905-921.
23. Jones A.T., Kjeldgaard M. Electron-density map interpretation. Methods Enzymol. 277:1997;173-208.
24. Howard A.J. Bourne P.E., Watenpaugh K.D. Proceedings from the Macromolecular Crystallographic Computing School, 1996. Crystallographic Computing. vol. 7:2001;105-165 Oxford Univ. Press, Oxford.
25. Wang Z., Harkins P.C., Ulevitch R.J., Han J., Cobb M.H., Goldsmith E.J. The structure of mitogen-activated protein kinase p38 at 2.1 Ang. resolution. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2327-2332.
26. Pav S., White D.M., Rogers S., Crane K.M., Cywin C.L., Davidson W., Hopkins J., Brown M.L., Pargellis C.A., Tong L. Crystallization and preliminary crystallographic analysis of recombinant human P38 MAP kinase. Protein Sci. 6:1997;242-245.
27. Otterbein L.R., Graceffa P., Dominguez R. The crystal structure of uncomplexed actin in the ADP state. Science. 293:2001;616-618.
28. Wilson K.P., McCaffrey P.G., Hsiao K., Pazhanisamy S., Galullo V., Bemis G.W., Fitzgibbon M.J., Caron P.R., Murcko M.A., Su M.S.S. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 4:1997;423-431.
29. Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R., Abdel-Meguid S., Adams J.L., Goldsmith E.J. Structural basis of inhibitor selectivity in MAP kinases. Structure. 6:1998;1117-1128.
30. Chang C.-I., Xu B., Akella R., Cobb M.H., Goldsmith E.J. Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. Mol. Cell. 9:2002;1241-1249.